Lupin, in a release issued to the BSE today, said the Court of Appeals for the Federal Circuit in the United States, on September 11, 2007, reversed a district court decision on Ramipril in its favor.The release added that the appeals court found the Aventis patent on Ramipril invalid. Aventis owns the 722 patent in question, and King Pharmaceuticals markets Altace.Ramipril is one of the ACE inhibitors useful for treating high blood pressure, and Altace revenue was over $900 million in the US (IMS MAT Jun 2007), the release said."We are really pleased that we won the appeal," Dr. Kamal K. Sharma, managing director, Lupin, said. "We are in the process of determining when we can enter the market. We believe that this is a land-mark decision, and is a strong testament of our IP capabilities."
